ML19324F963

Shine Medical Technologies, LLC - Cover Letter for Notice of Opportunity for Hearing and Petition for Leave to Intervene

ML19324F963
Person / Time
Site:	SHINE Medical Technologies
Issue date:	01/02/2020
From:	Theresa Lalain NRC/NRR/DANU
To:	Gregory P SHINE Medical Technologies
Lynch S
Shared Package
ML19324F962	List: ML19324F963 ML19324F964
References
EPID: L-2019-NEW-0004
Download: ML19324F963 (4)

Text

January 2, 2020 Gregory Piefer, Ph.D.

Chief Executive Officer SHINE Medical Technologies, LLC 101 E. Milwaukee Street, Suite 600 Janesville, WI 53545

SUBJECT:

SHINE MEDICAL TECHNOLOGIES, LLC - NOTICE OF OPPORTUNITY TO REQUEST A HEARING AND PETITION FOR LEAVE TO INTERVENE (EPID NO. L-2019-NEW-0004)

Dear Dr. Piefer:

By letter dated July 17, 2019 (Agencywide Documents Access and Management System (ADAMS) Accession No. ML19211C044) and supplemented by letter dated November 14, 2019 (ADAMS Accession No. ML19337A275), SHINE Medical Technologies, LLC (SHINE) submitted to the U.S. Nuclear Regulatory Commission (NRC) an operating license application for its proposed SHINE Medical Isotope Production Facility in accordance with the requirements contained in Title 10 of the Code of Federal Regulations (10 CFR) Part 50, Domestic Licensing of Production and Utilization Facilities. In accordance with 10 CFR Part 2, Agency Rules of Practice and Procedure, and Part 50, the NRC staff performed an acceptance review of the SHINE operating license application and, by letter dated October 8, 2019 (ADAMS Accession No. ML19276D411), accepted the application for docketing under Docket Number 50-608. The SHINE operating license application and supplement are located in ADAMS at Accession Nos. ML19211C143 and ML19331A832, respectively.

Enclosed is a copy of the Federal Register Notice affording any persons whose interest may be affected by the issuance of an operating license to SHINE an opportunity to file a request for a hearing and petition for leave to intervene with respect to the action within 60 days after the date of publication of the notice. Because the license application contains Sensitive Unclassified Non-Safeguards Information (SUNSI) and Safeguards Information (SGI), an included Order imposes procedures to obtain access to SUNSI and SGI for contention preparation.

G. Piefer If you have any questions, please contact Steven Lynch at (301) 415-1524 or by electronic mail at Steven.Lynch@nrc.gov.

Sincerely,

/RA/

Theresa Lalain, Acting Deputy Division of Advanced Reactors and Non-Power Production and Utilization Facilities Office of Nuclear Reactor Regulation Docket No. 50-608 Construction Permit No. CPMIF-001 cc: See next page

SHINE Medical Technologies, LLC Docket No. 50-608 cc:

Jeff Bartelme Bill McCoy Licensing Manager 1326 Putnam Avenue SHINE Medical Technologies, LLC Janesville, WI 53546 101 E. Milwaukee Street, Suite 600 Janesville, WI 53545 Alfred Lembrich 541 Miller Avenue Nathan Schleifer Janesville, WI 53548 General Counsel SHINE Medical Technologies, LLC 101 E. Milwaukee Street, Suite 600 Janesville, WI 53545 Christopher Landers Director, Office of Conversion National Nuclear Security Administration, NA-23 U.S. Department of Energy 1000 Independence Ave SW Washington, DC 20585 Mark Paulson Supervisor Radiation Protection Section Wisconsin Department of Health Services P.O. Box 2659 Madison, WI 53701-2659 Shelley Warwick Environmental Analysis Specialist-South Team Wisconsin Department of Natural Resources 3911 Fish Hatchery Road Fitchburg, WI 53711 Test, Research and Training Reactor Newsletter Attention: Ms. Amber Johnson Dept of Materials Science and Engineering University of Maryland 4418 Stadium Dr.

College Park, MD 20742-2115 Mark Freitag City Manager P.O. Box 5005 Janesville, WI 53547-5005

ML19324F962 (pkg) *concurred via e-mail OFFICE NRR/DANU/PM* NRR/DANU/LA* OGC* NRR/DANU/BC NRR/DANU/DD (A)

NAME SLynch NParker RAugustus GCasto TLalain DATE 11/20/19 11/25/19 12/18/19 1/2/2020 1/2/2020